PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease

Psychopharmacology

Volumn 188, Issue 4, 2006, Pages 509-520

  Kadir, Ahmadul ^a   Almkvist, Ove ^a,b   Wall, Anders ^c   Långström, Bengt ^c   Nordberg, Agneta ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b STOCKHOLM UNIVERSITY   (Sweden)

^c Uppsala Imanet   (Sweden)

Author keywords

11C nicotine binding; Alzheimer's disease (AD); Attention; Cognition; Nicotinic acetylcholine receptors (nAChRs); Positron emission tomography (PET)

Indexed keywords

NICOTINE C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; WATER O 15; CARBON; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR;

AGED; ALZHEIMER DISEASE; ARTICLE; ATTENTION; BINDING SITE; BRAIN BLOOD FLOW; BRAIN REGION; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DEPTH PERCEPTION; DRUG ABSORPTION; DRUG DISTRIBUTION; EPISODIC MEMORY; FEMALE; FRONTAL CORTEX; HUMAN; IN VIVO STUDY; MALE; NEUROPSYCHOLOGICAL TEST; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; BRAIN; CLINICAL TRIAL; DRUG EFFECT; MEMORY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SCINTISCANNING;

AGED; ALZHEIMER DISEASE; ATTENTION; BRAIN; CARBON RADIOISOTOPES; COGNITION; FEMALE; HUMANS; MALE; MEMORY; NEUROPSYCHOLOGICAL TESTS; NICOTINE; NICOTINIC AGONISTS; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, NICOTINIC;

EID: 33847250946     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-006-0447-7     Document Type: Article

References (78)

1. Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM (2002) Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry 159:738-745
2. Alhainen K, Helkala EL, Riekkinen P (1993) Psychometric discrimination of tetrahydroaminoacridine responders in Alzheimer patients. Dementia 4:54-58
3. Almkvist O, Jelic V, Amberla K, Hellstrom-Lindahl E, Meurling L, Nordberg A (2001) Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients. Dement Geriatr Cogn Disord 12:22-32
4. Anderson J (1995) A rapid and accurate method to realign PET-scans utilizing image edge information. J Nucl Med 36:657-669
5. Aubert I, Araujo DM, Cecyre D, Robitaille Y, Gauthier S, Quirion R (1992) Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases. J Neurochem 58:529-541
6. Backman L, Forsell Y (1994) Episodic memory functioning in a community-based sample of old adults with major depression: utilization of cognitive support. J Abnorm Psychol 103:361-370
7. Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti B, Davis JG, Constantine G, Mathis CA, Moore RY, DeKosky ST (2005) Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease. Neurosci Lett 380:127-132
8. Cabeza R, Nyberg L (2000) Imaging cognition II: an empirical review of 275 PET and fMRI studies. J Cogn Neurosci 12:1-47
9. Cahn-Weiner DA, Sullivan EV, Shear PK, Fama R, Lim KO, Yesavage JA, Tinklenberg JR, Pfefferbaum A (1999) Brain structural and cognitive correlates of clock drawing performance in Alzheimer's disease. J Int Neuropsychol Soc 5:502-509
10. Calhoun ME, Mao Y, Roberts JA, Rapp PR (2004) Reduction in hippocampal cholinergic innervation is unrelated to recognition memory impairment in aged rhesus monkeys. J Comp Neurol 475:238-246
11. Chefer SI, London ED, Koren AO, Pavlova OA, Kurian V, Kimes AS, Horti AG, Mukhin AG (2003) Graphical analysis of 2-[18F]FA binding to nicotinic acetylcholine receptors in rhesus monkey brain. Synapse 48:25-34
12. Coyle JT, Price DL, DeLong MR (1983) Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 219:1184-1190
13. Ding YS, Fowler JS, Logan J, Wang GJ, Telang F, Garza V, Biegon A, Pareto D, Rooney W, Shea C, Alexoff D, Volkow ND, Vocci F (2004) 6-[18F]Fluoro-A- 85380, a new PET tracer for the nicotinic acetylcholine receptor: studies in the human brain and in vivo demonstration of specific binding in white matter. Synapse 53:184-189
14. Duchek JM, Hunt L, Ball K, Buckles V, Morris JC (1997) The role of selective attention in driving and dementia of the Alzheimer type. Alzheimer Dis Assoc Disord 1(Suppl 11):48-56
15. Flores CM, Rogers SW, Pabreza LA, Wolfe BB, Kellar KJ (1992) A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol 41:31-37
16. Foldi NS, Lobosco JJ, Schaefer LA (2002) The effect of attentional dysfunction in Alzheimer's disease: theoretical and practical implications. Semin Speech Lang 23:139-150
17. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198
18. Foster NL, Chase TN, Fedio P, Patronas NJ, Brooks RA, Di Chiro G (1983) Alzheimer's disease: focal cortical changes shown by positron emission tomography. Neurology 33:961-965
19. Gallezot JD, Bottlaender M, Gregoire MC, Roumenov D, Deverre JR, Coulon C, Ottaviani M, Dolle F, Syrota A, Valette H (2005) In vivo imaging of human cerebral nicotinic acetylcholine receptors with 2-18F-fluoro-A-85380 and PET. J Nucl Med 46:240-247
20. Guan ZZ, Zhang X, Ravid R, Nordberg A (2000) Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. J Neurochem 74:237-243
21. Guillozet AL, Weintraub S, Mash DC, Mesulam MM (2003) Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol 60:729-736
22. Gundisch D, Koren AO, Horti AG, Pavlova OA, Kimes AS, Mukhin AG, London ED (2005) In vitro characterization of 6-[18F] fluoro-A-85380, a high-affinity ligand for alpha4beta2* nicotinic acetylcholine receptors. Synapse 55:89-97
23. Haxby JV, Duara R, Grady CL, Cutler NR, Rapoport SI (1985) Relations between neuropsychological and cerebral metabolic asymmetries in early Alzheimer's disease. J Cereb Blood Flow Metab 5:193-200
24. Herholz K, Adams R, Kessler J, Szelies B, Grond M, Heiss W (1990) Criteria for the diagnosis of Alzheimer's disease with positron emission tomography. Dementia 1:156-164
25. Herholz K, Nordberg A, Salmon E, Perani D, Kessler J, Mielke R, Halber M, Jelic V, Almkvist O, Collette F, Alberoni M, Kennedy A, Hasselbalch S, Fazio F, Heiss WD (1999) Impairment of neocortical metabolism predicts progression in Alzheimer's disease. Dement Geriatr Cogn Disord 10:494-504
26. Herscovitch P, Markham J, Raichle ME (1983) Brain blood flow measured with intravenous H2(15)O. I. Theory and error analysis. J Nucl Med 24:782-789
27. Ikonomovic MD, Mufson EJ, Wuu J, Cochran EJ, Bennett DA, DeKosky ST (2003) Cholinergic plasticity in hippocampus of individuals with mild cognitive impairment: correlation with Alzheimer's neuropathology. J Alzheimers Dis 5:39-48
28. Jones GM, Sahakian BJ, Levy R, Warburton DM, Gray JA (1992) Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology (Berl) 108:485-494
29. Kadir A, Almkvist O, Wall A, Darreh-Shori T, Grut M, Strandberg B, Ringheim A, Erikson B, Blomquist G, Långström B, Nordberg A (2006a) PET imaging of acetylcholinesterase activity and nicotine binding in galantamine treated AD patients. In preparation
30. Kadir A, Darreh-Shori T, Almkvist O, Wall A, Långström B, Nordberg A (2006b) Changes in the brain 11C-nicotine binding sites in mild AD patients following rivastigmine treatment as assessed by PET. In preparation
31. Lawrence AD, Sahakian BJ (1995) Alzheimer disease, attention, and the cholinergic system. Alzheimer Dis Assoc Disord 2(Suppl 9):43-49
32. Lezak M (1995) Neuropsychological assessment, 3rd edn. Oxford University Press, London, UK
33. Lundqvist H, Nordberg A, Hartvig P, Langstrom B (1998) (S)-(?)-[11C]nicotine binding assessed by PET: a dual tracer model evaluated in the rhesus monkey brain. Alzheimer Dis Assoc Disord 12:238-246
34. Luria A (1966) Higher cortical functions in man. Basic Books, New York
35. Maziere M, Delforge J (1995) PET imaging [11C]nicotine: historical aspects. In: Domino E (ed) Brain imaging of nicotine and tobacco smoking. NPP Books, Ann Arbor, pp 13-28
36. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34:939-944
37. Mega MS, Dinov ID, Porter V, Chow G, Reback E, Davoodi P, O'Connor SM, Carter MF, Amezcua H, Cummings JL (2005) Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study. Arch Neurol 62:721-728
38. Mogg AJ, Jones FA, Pullar IA, Sharples CG, Wonnacott S (2004) Functional responses and subunit composition of presynaptic nicotinic receptor subtypes explored using the novel agonist 5-iodo-A-85380. Neuropharmacology 47:848-859
39. Nagahama Y, Okina T, Suzuki N, Nabatame H, Matsuda M (2005) Neural correlates of impaired performance on the clock drawing test in Alzheimer's disease. Dement Geriatr Cogn Disord 19:390-396
40. Newhouse PA, Sunderland T, Tariot PN, Blumhardt CL, Weingartner H, Mellow A, Murphy DL (1988) Intravenous nicotine in Alzheimer's disease: a pilot study. Psychopharmacology (Berl) 95:171-175
41. Nobili F, Brugnolo A, Calvini P, Copello F, De Leo C, Girtler N, Morbelli S, Piccardo A, Vitali P, Rodriguez G (2005) Resting SPECT-neuropsychology correlation in very mild Alzheimer's disease. Clin Neurophysiol 116:364-375
42. Nordberg A (1999) PET studies and cholinergic therapy in Alzheimer's disease. Rev Neurol (Paris) 4(Suppl 155):S53-S63
43. Nordberg A (2001) Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications. Biol Psychiatry 49:200-210
44. Nordberg A (2006) Visualization of nicotinic and muscarinic receptors in brain by positron emission tomography. In: Ezio G, Pepeu G (eds) The brain cholinergic system. Martin Dunitz, London
45. Nordberg A, Winblad B (1986) Reduced number of [3H]nicotine and [3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains. Neurosci Lett 72:115-119
46. Nordberg A, Hartvig P, Lilja A, Viitanen M, Amberla K, Lundqvist H, Andersson Y, Ulin J, Winblad B, Langstrom B (1990) Decreased uptake and binding of 11C-nicotine in brain of Alzheimer patients as visualized by positron emission tomography. J Neural Transm Park Dis Dement Sect 2:215-224
47. Nordberg A, Alafuzoff I, Winblad B (1992) Nicotinic and muscarinic subtypes in the human brain: changes with aging and dementia. J Neurosci Res 31:103-111
48. Nordberg A, Lundqvist H, Hartvig P, Lilja A, Langstrom B (1995) Kinetic analysis of regional (S)(?)11C-nicotine binding in normal and Alzheimer brains - in vivo assessment using positron emission tomography. Alzheimer Dis Assoc Disord 9:21-27
49. Nordberg A, Lundqvist H, Hartvig P, Andersson J, Johansson M, Hellstrom-Lindahi E, Langstrom B (1997) Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: effect of tacrine treatment. Dement Geriatr Cogn Disord 8:78-84
50. Nordberg A, Amberla K, Shigeta M, Lundqvist H, Viitanen M, Hellstrom-Lindahl E, Johansson M, Andersson J, Hartvig P, Lilja A, Langstrom B, Winblad B (1998) Long-term tacrine treatment in three mild Alzheimer patients: effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive abilities. Alzheimer Dis Assoc Disord 12:228-237
51. Ober BA, Jagust WJ, Koss E, Delis DC, Friedland RP (1991) Visuoconstructive performance and regional cerebral glucose metabolism in Alzheimer's disease. J Clin Exp Neuropsychol 13:752-772
52. Pabreza LA, Dhawan S, Kellar KJ (1991) [3H]Cytisine binding to nicotinic cholinergic receptors in brain. Mol Pharmacol 39:9-12
53. Paterson D, Nordberg A (2000) Neuronal nicotinic receptors in the human brain. Prog Neurobiol 61:75-111
54. Perry RJ, Hodges JR (2000) Fate of patients with questionable (very mild) Alzheimer's disease: longitudinal profiles of individual subjects' decline. Dement Geriatr Cogn Disord 11:342-349
55. Perry E, Martin-Ruiz C, Lee M, Griffiths M, Johnson M, Piggott M, Haroutunian V, Buxbaum JD, Nasland J, Davis K, Gotti C, Clementi F, Tzartos S, Cohen O, Soreq H, Jaros E, Perry R, Ballard C, McKeith I, Court J (2000) Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. Eur J Pharmacol 393:215-222
56. Potter A, Corwin J, Lang J, Piasecki M, Lenox R, Newhouse PA (1999) Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease. Psychopharmacology (Berl) 142:334-342
57. Raichle ME, Martin WR, Herscovitch P, Mintun MA, Markham J (1983) Brain blood flow measured with intravenous H2(15)O. II. Implementation and validation. J Nucl Med 24:790-798
58. Robbins TW, McAlonan G, Muir JL, Everitt BJ (1997) Cognitive enhancers in theory and practice: studies of the cholinergic hypothesis of cognitive deficits in Alzheimer's disease. Behav Brain Res 83:15-23
59. Robertson LC, Lamb MR, Knight RT (1988) Effects of lesions of temporal-parietal junction on perceptual and attentional processing in humans. J Neurosci 8:3757-3769
60. Rusted JM, Graupner L, Tennant A, Warburton DM (1998) Effortful processing is a requirement for nicotine-induced improvements in memory. Psychopharmacology (Berl) 138:362-368
61. Rusted JM, Newhouse PA, Levin ED (2000) Nicotinic treatment for degenerative neuropsychiatric disorders such as Alzheimer's disease and Parkinson's disease. Behav Brain Res 113:121-129
62. Sahakian BJ, Jones GM (1991) The effects of nicotine on attention, information processing, and working memory in patients with dementia of the Alzheimer type. In: Adlkofer F, Thruau K (eds) Effects of nicotine on biological system. Birkhauser Verlag, Basel
63. Sahakian BJ, Owen AM, Morant NJ, Eagger SA, Boddington S, Crayton L, Crockford HA, Crooks M, Hill K, Levy R (1993) Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB. Psychopharmacology (Berl) 110:395-401
64. Sihver W, Fasth KJ, Horti AG, Koren AO, Bergstrom M, Lu L, Hagberg G, Lundqvist H, Dannals RF, London ED, Nordberg A, Langstrom B (1999) Synthesis and characterization of binding of 5-[76Br]bromo-3-[[2(S)-azetidinyl]methoxy] pyridine, a novel nicotinic acetylcholine receptor ligand, in rat brain. J Neurochem 73:1264-1272
65. Snaedal J, Johannesson T, Jonsson JE, Gylfadottir G (1996) The effects of nicotine in dermal plaster on cognitive functions in patients with Alzheimer's disease. Dementia 7:47-52
66. Teipel SJ, Willoch F, Ishii K, Burger K, Drzezga A, Engel R, Bartenstein P, Moller HJ, Schwaiger M, Hampel H (2005) Resting state glucose utilization and the CERAD cognitive battery in patients with Alzheimer's disease. Neurobiol Aging 27(5):681-690
67. Vellas B, Cunha L, Gertz HJ, De Deyn PP, Wesnes K, Hammond G, Schwalen S (2005) Early onset effects of galantamine treatment on attention in patients with Alzheimer's disease. Curr Med Res Opin 21:1423-1429
68. Vitaliano PP, Breen AR, Albert MS, Russo J, Prinz PN (1984) Memory, attention, and functional status in community-residing Alzheimer type dementia patients and optimally healthy aged individuals. J Gerontol 39:58-64
69. Voytko ML, Olton DS, Richardson RT, Gorman LK, Tobin JR, Price DL (1994) Basal forebrain lesions in monkeys disrupt attention but not learning and memory. J Neurosci 14:167-186
70. Walsh DM, Selkoe DJ (2004) Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44: 181-193
71. Warpman U, Nordberg A (1995) Epibatidine and ABT 418 reveal selective losses of alpha 4 beta 2 nicotinic receptors in Alzheimer brains. Neuroreport 6:2419-2423
72. Watson CCND, Casey ME et al (1997) Evaluation of simulation based scatter correction for 3D PET cardiac imaging. IEEE Trans Nucl Sci 21:136-144
73. Wechsler D (1981) Wechsler Adult Intelligence Scale - revised manual. Psychological Corporation, New York
74. Wevers A, Monteggia L, Nowacki S, Bloch W, Schutz U, Lindstrom J, Pereira EF, Eisenberg H, Giacobini E, de Vos RA, Steur EN, Maelicke A, Albuquerque EX, Schroder H (1999) Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer's disease: histotopographical correlation with amyloid plaques and hyperphosphorylated-tau protein. Eur J Neurosci 11:2551-2565
75. White HK, Levin ED (1999) Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease. Psychopharmacology (Berl) 143:158-165
76. White HK, Levin ED (2004) Chronic transdermal nicotine patch treatment effects on cognitive performance in age-associated memory impairment. Psychopharmacology (Berl) 171:465-471
77. Wilson AL, Langley LK, Monley J, Bauer T, Rottunda S, McFalls E, Kovera C, McCarten JR (1995) Nicotine patches in Alzheimer's disease: pilot study on learning, memory, and safety. Pharmacol Biochem Behav 51:509-514
78. Yu WF, Guan ZZ, Bogdanovic N, Nordberg A (2005) High selective expression of alpha7 nicotinic receptors on astrocytes in the brains of patients with sporadic Alzheimer's disease and patients carrying Swedish APP 670/671 mutation: a possible association with neuritic plaques. Exp Neurol 192:215-225